Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18431308 | 0.89 | FURIN (0.41) | FURINHTTSIRT2SIRT1SIRT3 | |
| SCHEMBL19389191 | 0.87 | SIRT2 (0.41) | FURINHTTSIRT2SIRT1SIRT3 | |
| SCHEMBL22541220 | 0.86 | FURIN (0.40) | FURINHTTSIRT2SIRT1SIRT3 | |
| SCHEMBL25018417 | 0.86 | FURIN (0.40) | FURINHTTSIRT2SIRT1SIRT3 | |
| SCHEMBL21883411 | 0.86 | SIRT2 (0.39) | SIRT2SIRT1SIRT3SMN1; SMN2SIRT5 | |
| SCHEMBL25490828 | 0.84 | HTT (0.41) | FURINHTTSIRT2SIRT1SIRT3 | |
| SCHEMBL19633170 | 0.83 | SIRT2 (0.39) | FURINHTTSIRT2SIRT1SIRT3 | |
| SCHEMBL19633304 | 0.82 | SPHK1 (0.41) | SIRT2SIRT1SIRT3SMN1; SMN2SIRT5 | |
| SCHEMBL25124339 | 0.82 | FURIN (0.43) | FURINHTTSIRT2SIRT1SIRT3 | |
| SCHEMBL24329149 | 0.82 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SMN1; SMN2SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10780096-B2 | Pyrrolobenzodiazepine-antibody conjugates | ADC THERAPEUTICS SA (CH) | 2020-09-22 | — | — | US | disclosed |
| US-20170258934-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258934-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | IL2RA, CD2, CD4 | FURIN 3172/4885HTT 2283/4885SIRT2 663/4885 |
| US-10780096-B2 | Pyrrolobenzodiazepine-antibody conjugates | IL2RA, CD2, CD4 | FURIN 3172/4885HTT 2283/4885SIRT2 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.